Medical Diagnostics and Therapeutics
Organization: Indiana University
Hematopoietic stem cell development, urology diagnostics, cancer diagnostics, idiopathic pulmonary fibrosis therapeuti.
Development of Vaccines & Therapeutics
Organization: Mayo Clin
A number of researchers at Mayo Clinic are actively involved in the development and testing of next-generation vaccines for infectious diseases and cancer. Most of these programs have evolved from the basic study of disease biology and immune responses to development of antigenic molecules and preclinical testing in animal models of disease. In addition, our researchers are actively working on identifying novel therapeutic targets and treatment mechanisms/drugs. Mayo Clinic physicians and researchers are recognized experts in immunology and ...
Organization: New York University
The NYU Cancer Center is an NCI-designated Cancer Center with a 17 member translational research program. Distinguished faculty include Dr. Sylvia Formenti and Dr. Robert Schneider (discovered the toggle switch that controls recruitment of blood vessels and growth factors in breast cancer), Dr. Danny Reinberg (molecular mechanisms of epigenetics), Dr. Nina Bharadwaj (Cancer vaccines), Dr. Ramanuj Dasgupta (new therapies targeting Wnt for colorectal cancer) and Eva Hernando (role of micro RNAs in melanoma).
Cdk6 as a Marker for Breast Cancer
Organization: National Jewish Health
State of Development - Method tested in vitro: No cdk6 or considerably lower levels of cdk6 were detected in breast tumor-derived cell lines compare to healthy breast cells. Breast tumor-derived cell lines cells overexpressing cdk6 exhibited a much reduced growth rate compare to the control cell lines. Histologic studies using tissue from breast cancer patients show a severely decreased level of cdk6. Further R&D Required - Demonstrating reliability of cdk6 as a predictor of in vivo tumor cell growth.
ARL-1 Specific Antibodies and ARL-1 Biomarker
Organization: Southern Illinois University Med School
The aldo-keto reductase family 1 B10 (AKR1B10 or ARL-1) protein is normally expressed in healthy colon tissue, but is decreased or absent in colorectal cancer and precancerous conditions. Conversely, ARL-1 is normally low or absent in breast, prostate, liver, and lung tissues, but is over-expressed in cancers of these tissues. The first part of this invention covers a novel antibody, which may be monoclonal or polyclonal, against ARL-1 protein. The antibody is both sensitive and highly specific to ARL-1 and has great utility as a cancer ...
MAGP-2: An Extracellular Factor Shown to have Pro-Angiogenic Properties in vivo
Organization: National Jewish Health
Our scientists have shown the following: In vitro: MAGP-2 is over expressed in human uterine tumor samples Endothelial cell expression of MAGP-2 increases during angiogenesis in vitro MAGP-2 stimulates angiogenic sprouting in 3-dimensional collagen cultures MAGP-2 increases endothelial cell proliferation and invasion in vitro In vivo: Significant enhancement of neovascularization when MAGP-2 was implanted into mice through matrigel plugs MAGP-2 increases tumor size and angiogenesis in mice
Compounds For Binding to ERα/β and GPR30 to Treat Disease States or Conditions
Organization: STC UNM
Compounds specific for binding to estrogen receptors alpha/beta and GPR30 for use in treating disease states and conditions mediated through these receptors. Additionally, the present invention includes a method for identifying chemical compounds that interact with estrogen-related receptors alpha/beta and GPR30.
SUB-TYPE SPECIFIC SERUM BIOMARKERS FOR EARLY DIAGNOSIS OF BREAST CANCERS
Organization: University of California, San Francisco (UCSF)
Investigators at three institutions have conducted a multi-site investigation to identify cancer-associated glycosites on glycoproteins that may circulate in patients’ blood. Specifically, the study targeted triple negative breast cancer (TNBC), so-called because it lacks expression of the estrogen and progesterone receptors and displays moderate levels of the human epidermal growth factor receptor 2 (HER2). This highly aggressive cancer subtype is of particular clinical interest because there are no targeted therapies for its ...
A Novel Dynamic Shielding Applicator for High Dose Rate Brachytherapy
Organization: University of California, San Diego (UC San Diego)
Researchers at UC San Diego have designed a novel “dynamic” modulated brachytherapy (DMBT) applicator, based on robotic controls, which allows isotropic radiation to directionally conform to a patient’s specific anatomy on a daily basis for accurate tumorcidal dose delivery while drastically reducing radiation and toxicity to the surrounding healthy tissues.The movable tungsten applicator, with dynamic window, encapsulates the radiation source and is programmed to translate along the axial dimension of the applicator ...
Inhibitors of CDK1 for Cancer Stem Cell Treatment
Organization: University of Pittsburgh
Inhibitors of Dopamine D1 Receptor for Cancer Stem Cell Treatment
Organization: University of Pittsburgh
Kinase inhibitors for Cancer Stem Cell Treatment
Organization: University of Pittsburgh
Protein biomarker set for personalized treatment of ERα-positive breast cancer
Organization: German Cancer Research Ctr (DKFZ)
Proteome profiling was carried out for luminal breast cancer by using reverse phase protein microarrays (RPPA) as the experimental platform. The resulting quantitative data was analyzed using a combination of different statistical classification methods aimed at a robust discrimination between low risk and high risk tumors. This approach consistently identified a protein signature comprising the following proteins: RPS6, nucleoside- diphosphate kinase (NDKA), and caveolin-1. In high risk tumors, RPS6 and NDKA are upregulated. On ...
Novel Mouse Model for Breast Cancer Through Activation of PIK3C, RDLP TP #673
Organization: Hospital for Sick Children
The present innovation relates to the development of a novel mouse model for breast cancer and other cancers. Investigators at SickKids have used the ROSA26 loxP-stop-loxP system to knock-in various alleles of PIK3Ca, including the wild type gene as well as mutants that are commonly found in human breast cancer. These mice can be used to induce activated PIK3Ca in any tissue or cell type simply through expression of the cre recombinase. When mice with either PIK3CaE545K or PIK3CaH1047R allele are activated with MMTV-Cre, they develop ...
Organization: Hospital for Sick Children
The invention encompasses the use of polynucleotide sequences encoding ß-parvin, a newly identified tumor suppressor gene in breast cancer. The invention includes diagnostic methods using the ß-parvin polynucleotides and/or peptides and embodiments thereof as diagnostic or therapeutic tools for breast cancer. Also included, is the use of ß-parvin polunucleotides and/or peptides in assays to identify pharmacological agents for the treatment of breast cancer.
siRNAs and their targets that selectively inhibit cancer stem cells
Organization: University of Pittsburgh
Injection of a Radioactive Dye for Sentinel Lymph Node Identification
Organization: Louisiana State University Health Sciences Center New Orleans
Sentinel lymph node biopsy is an established alternative to complete lymph node dissection in patients with breast cancer and melanoma. Greater than 90% of new breast cancers will have a sentinel lymph node biopsy (210,000 new breast cancer patients/year x 90% rate of sentinel node procedures = 189,000 uses/year). A researcher at the LSU Health Sciences Center in New Orleans has developed a new intraoperative injection approach utilizing a novel, radiolabeled methylene blue dye for sentinel lymph node identification. This patented ...
Gene Signature for Invasive Cancer
Organization: Stanford University
Organization: Stanford University
Use of Gremlin 1 in diagnosis and prognosis of cancers
Organization: Stanford University
Novel Splice Variant of the EGF Receptor
Organization: Stanford University
Organization: Stanford University
Novel Dynamic Arc Technique for Partial Breast Radiotherapy
Organization: Stanford University
Neuregulin Antagonists and Use Thereof in Treating Cancer
Organization: Stanford University
C-Path: computer-aided pathology analysis for cancer tissue
Organization: Stanford University
Probes for in vivo and in vitro analysis of RNA structure
Organization: Stanford University
RNA structure plays important roles in practically every facet of gene regulation and has been found to be important in diseases such as cancer, but the paucity of structural probes that function in vivo has limited current understanding. Here we design, synthesize, and demonstrate two novel chemical probes that enable accurate RNA structural analysis in living cells.
Targeting Peptide for the ErbB-2 Receptor
Organization: University of Missouri Columbia
STATE OF DEVELOPMENT: -Ready to use. LICENSING POTENTIAL: -University seeks licensee with potential to commercialize
Novel Amide Derivatives of Ethacrynic Acid for Cancer Therapy
Organization: University of California, San Diego (UC San Diego)
Although the approved drug ethacrynic acid (EA) kills CLL cells at lower doses than normal (non-cancerous) B cells, its strong diuretic activity makes it impractical for patient treatment. Researchers at UC San Diego have developed amide derivatives of EA that show increased potency against CLL cells without diuretic activity. These proprietary compounds inhibit Wnt signaling pathways (which appear to be more active in CLL cells) resulting in reduced survival of tumor cells.
A Method to Diagnose the Risk for and Prevent Breast Inflammation and Breast Cancer
Organization: Indiana Univ-Purdue University Indianapolis
UC San Diego researchers have invented new methods to detect entry of inflammatory mediators in normal (or diseased) breasts as well as ways to prevent the inflammation. Although the disclosed techniques focus on breast cancer, this diagnostic technology may be applicable to other similar diseased conditions, including prostate inflammation and cancer, ovarian and colon inflammation and cancer, and certain forms of brain inflammation and cancer. More generally, this technology is applicable to inflammation and cancers derived from epithelial ...
A Novel Dynamic Shielding Applicator for High Dose Rate Brachytherapy
Organization: Indiana Univ-Purdue University Indianapolis
Researchers at UC San Diego have designed a novel “dynamic” modulated brachytherapy (DMBT) applicator, based on robotic controls, which allows isotropic radiation to directionally conform to a patient’s specific anatomy on a daily basis for accurate tumorcidal dose delivery while drastically reducing radiation and toxicity to the surrounding healthy tissues.The movable tungsten applicator, with dynamic window, encapsulates the radiation source and is programmed to translate along the axial dimension of the applicator ...
Organization: Indiana Univ-Purdue University Indianapolis
This novel technology is a way to diagnose and treat CLL, breast cancer, and other cancers. A monoclonal antibody has been generated by UC San Diego against a receptor which is implicated in the progression of cancer. This protein named ROR1 is expressed on CLL B cells, but it is not present in normal lymphocytes.
Novel Amide Derivatives of Ethacrynic Acid for Cancer Therapy
Organization: Indiana Univ-Purdue University Indianapolis
Although the approved drug ethacrynic acid (EA) kills CLL cells at lower doses than normal (non-cancerous) B cells, its strong diuretic activity makes it impractical for patient treatment. Researchers at UC San Diego have developed amide derivatives of EA that show increased potency against CLL cells without diuretic activity. These proprietary compounds inhibit Wnt signaling pathways (which appear to be more active in CLL cells) resulting in reduced survival of tumor cells.
Wnt and Frizzled Receptors as Targets of Immunotherapy in Human Cancers
Organization: Indiana Univ-Purdue University Indianapolis
UC San Diego researchers have identified proprietary methods for using antibodies to treat head and neck, as well as breast cancer, by specifically targeting components of the Wnt signaling pathway. Issued claims cover use of antibodies for immunotherapy [4] and for evaluating expression of components of the Wnt/Frizzled signaling pathway in human cancers. Such assessment may prove vital for evaluating the utility of drugs for specific patient populations and the efficacy of a treatment.
Method and System for Fractal-Based Analysis of Medical Image Texture
Organization: Indiana Univ-Purdue University Indianapolis
Mammographic parenchymal patterns have been shown to be associated with breast cancer risk. Fractal�-based texture analyses, including box-counting methods and Minkowski dimension, were performed within parenchymal regions of normal mammograms of BRCAI/BRCA2 gene mutation carriers and within mammograms of women at low risk for developing breast cancer. Receiver Operating Characteristic (ROC) analysis was used for assessing the performance of the computerized radiographic markers in the task of distinguishing between high- and low-risk ...
Basal Markers in Breast Cancer
Organization: Indiana Univ-Purdue University Indianapolis
Organization: Indiana Univ-Purdue University Indianapolis
Organization: Indiana Univ-Purdue University Indianapolis
Novel Splice Variant of the EGF Receptor
Organization: Indiana Univ-Purdue University Indianapolis
microRNA profile of cancer stem cells
Organization: Indiana Univ-Purdue University Indianapolis
RB Functional Status as a Determinant for Breast Cancer Therapy
Organization: Indiana Univ-Purdue University Indianapolis
Cisplatin resistant clones of Capan-1 with/without BRCA2 mutations
Organization: Indiana Univ-Purdue University Indianapolis
Organization: University of California, Los Angeles (UCLA)
Dr. Eric Vilain and colleagues in UCLA’s Department of Human Genetics have identified a mutant form of a known tumor suppressor, CDKN1C, that leads to inhibition of cellular growth through a novel mechanism and that may be useful as a therapeutic. CDKN1C negatively regulates growth by inhibiting the cell cycle at the G0-G1 transition. Loss of function of CDKN1C due to gene silencing decreases protein production and/or increases protein degradation and has been associated with a plethora of cancers including, not limited to: liver, ...
RB Functional Status as a Determinant for Breast Cancer Therapy
Organization: University of Cincinnati
Breast cancer is the second leading cause of cancer death in US women, after lung cancer. It is estimated that about 200,000 women in the United States will be diagnosed with invasive breast cancer in 2006 and that about 40,000 women will die from the disease.In a recently published article in the Journal of Clinical Investigation, Dr. Erik Knudsen and colleagues at the University of Cincinnati discovered a link between inactivation of the retinoblastoma (RB) tumor suppressor and the response of cancer cells to anti-tumor therapies, including ...
Gene Signature for Invasive Cancer
Organization: Stanford University
Organization: Stanford University
Use of Gremlin 1 in diagnosis and prognosis of cancers
Organization: Stanford University
Novel Splice Variant of the EGF Receptor
Organization: Stanford University
Organization: Stanford University
Gene and Protein for Specific Treatment of Adenocarcinomas
Organization: Stanford University
Novel Dynamic Arc Technique for Partial Breast Radiotherapy
Organization: Stanford University
Neuregulin Antagonists and Use Thereof in Treating Cancer
Organization: Stanford University
High affinity SIRP-alpha reagents for CD47 blockade
Organization: Stanford University
C-Path: computer-aided pathology analysis for cancer tissue
Organization: Stanford University
SHAPE reagents — probes for in vivo and in vitro analysis of RNA structure
Organization: Stanford University
RNA structure plays important roles in practically every facet of gene regulation and has been found to be important in diseases such as cancer, but the paucity of structural probes that function in vivo has limited current understanding. Here we design, synthesize, and demonstrate two novel chemical probes that enable accurate RNA structural analysis in living cells.
A breast cancer prognostic test for clinical outcome
Organization: McGill University
It is increasingly evident that breast cancer outcome is strongly influenced by signals emanating from tumor-associated stroma. However, little is known about how gene expression changes in this tissue affect tumor progression. Here, we compare gene expression profiles from laser capture-microdissected tumor-associated versus matched normal stroma, and derive transcriptional profiles strongly associated with clinical outcome. We present a stroma-derived predictor that generates new information to stratify disease endpoint, independent of ...
Organization: Rutgers University
2009-010 Image Analysis Based Recurrence Predictoin Of ER Breast Cancers
Organization: Rutgers University
Oral Formulation of Fenretinide With Improved Bioavailability
Organization: Children's Hospital Los Angeles
Nanoparticle Assembly Method for Phototherapeutic Materials
Organization: Rice University
Predictive marker for taxane responsiveness of cancer patients
Organization: University of Alberta
University of Alberta researchers have identified a predictive marker to screen patients that are being considered for taxane-based chemotherapy. Elevated levels of this protein marker correlate with increased breast cancer patient survival after adjuvant-taxane treatment. In vitro experiments using siRNA to knock-down protein expression demonstrate that the marker is a critical effector molecule in the mechanism of action of taxane induced cytotoxicity. Physicians will now be able to make more informed treatment decisions in regards to ...
Fluorinated Fructose Derivatives for PET Imaging
Organization: University of Alberta
In breast cancer, the glucose/fructose transporter GLUT2 and the fructose transporter GLUT5 have been shown to be overexpressed in many breast tumours, suggesting that fructose-based analogues would be useful for the improved imaging of breast cancer. Dr. Chris Cheeseman and colleagues at the University of Alberta have recently designed and synthesized a new class of fluorinated fructose compounds. Such fructose-based radiopharmaceuticals have the potential to be used during in vivo PET imaging of breast cancer. One such compound, ...
Breast cancer model mice (BRCA1- conditional KO mice)
Organization: Columbia Tech Ventures
Organization: WORLDiscoveries - University of Western Ontario
This technology concerns separate inventions to specific compositions of hyaluronan (HA) fragments and/or agents useful for wound healing or the treatment of cancer. In some cancers, e.g., prostate and breast, HA levels correlate well with malignancy and poor prognosis. The inventors discovered an unexpected correlation between a narrow range of sizes of HA fragments and the stimulation of cell migration and proliferation. Based on this new knowledge and the correlation between HA and cancer, currently marketed compositions of HA may contain ...
Multiplexed Point-of-Care Breast Cancer Marker Detection System
Organization: University of California, Davis (UC Davis)
The presence and advancement of tumors has been shown to be associated with the expression of certain molecular markers. However, currently no single ideal marker exists for breast cancer. Researchers at the University of California, Davis and the Lawrence Livermore National Laboratory (LLNL) have developed a multiplexed immunoassay to measure a panel of five related molecular markers to achieve more relevant and reliable information for diagnosis of breast cancer. Compared to current breast cancer detection methods, which are associated with ...
Breast CT Scanner for Early Cancer Detection
Organization: University of California, Davis (UC Davis)
Researchers at the University of California, Davis have invented new devices and methods for early breast cancer detection through computed tomography (CT) imaging. These inventions enable better diagnosis and evaluation of breast tumors than current methods, and make possible new methods for delivering therapy to breast tumors. CT imaging is clearly recognized as superior to traditional x-ray imaging. However, x-rays are still the standard in mammography because image quality and radiation dose have been difficult obstacles to the adoption ...
A Soy-peptide to Prevent Cancer
Organization: University of California, Davis (UC Davis)
Research into lunasin, a peptide derived from soybean, has shown its anti-neoplastic properties (e.g., in cell transformation, foci formation, etc.) through its ability to control gene expression, but nothing is known about which specific genes fundamental to carcinogenesis are regulated by lunasin.Researchers at the University of Califorina, Davis have identified specific target genes in malignant cells whose expression profile is altered in response to lunasin exposure. Gene expression profiling reveals that lunasin up-regulates ...
A Human Inflammatory Breast Carcinoma Xenograft Model of the Intravasation Step of Metastasis
Organization: University of California, Los Angeles (UCLA)
UCLA researchers have developed the first transplantable human inflammatory carcinoma xenograft, designated MARY-X. Inflammatory breast carcinomas are one of the most aggressive human cancers, exhibiting an exaggerated degree of intravasation in situ and manifesting into florid lymphatic and vascular invasions. Therefore, MARY-X provides a good experimental model to dissect the molecular processes of intravasation. Additionally, comparison studies of inflammatory breast carcinoma xenografts in nude mice to the pathogenesis of the disease ...
Diagnostic and Therapeutic Methods Using the H37 Tumor Suppressor Gene
Organization: University of California, Los Angeles (UCLA)
Researchers at the University of California have identified a novel tumor suppressor gene H37 (also known as RBM5) which maps to lung cancer tumor suppressor locus 3p21.3. In addition, they have demonstrated that H37 has manifold, prominent tumor suppressor characteristics: 1) Decreased expression of H37 mRNA/protein in ~75 percent of the primary lung tumors compared with adjacent normal lung epithelia, 2) Growth inhibition, in vitro/vivo, of lung cancer cells induced by H37, and 3) H37s tumor suppression mechanism through G1/S arrest and ...
Organization: University of California, San Francisco (UCSF)
BACKGROUND: Breast cancer is one of the most commonly diagnosed cancers among women in the US. There are 2.4 million women living with breast cancer in the US and upwards of ~180,000 new cases each year. Breast cancer tumors are currently evaluated on the basis of several histopathological features including tumor size, grade, and lymph node status, all of which contribute to assessing the overall stage of cancer development. In addition, hormone receptor (ER, PR) and HER2 expression in tumors, together with the histopathological features, ...
A Method to Diagnose the Risk for and Prevent Breast Inflammation and Breast Cancer
Organization: University of California, San Diego (UC San Diego)
UC San Diego researchers have invented new methods to detect entry of inflammatory mediators in normal (or diseased) breasts as well as ways to prevent the inflammation. Although the disclosed techniques focus on breast cancer, this diagnostic technology may be applicable to other similar diseased conditions, including prostate inflammation and cancer, ovarian and colon inflammation and cancer, and certain forms of brain inflammation and cancer. More generally, this technology is applicable to inflammation and cancers derived from epithelial ...
Organization: University of California, San Diego (UC San Diego)
This novel technology is a way to diagnose and treat CLL, breast cancer, and other cancers. A monoclonal antibody has been generated by UC San Diego against a receptor which is implicated in the progression of cancer. This protein named ROR1 is expressed on CLL B cells, but it is not present in normal lymphocytes.
An Intraductal Approach to the Breast
Organization: University of California, Los Angeles (UCLA)
Anti-Human Deoxycytidine Kinase (dCK) Monoclonal Antibody
Organization: University of California, Los Angeles (UCLA)
Pro-Drug Conjugates Able to Deliver Precise Ratios of Active Drugs
Organization: University of California, San Diego (UC San Diego)
To date, the efficacy of combination drug therapy has been severely limited by the fact that each drug has a unique pharmacokinetic profile, which makes it impossible to control the molar ratio of different drugs taken up by the same diseased cells. Inventors at UC San Diego have developed a proprietary nanoparticle that is able to deliver defined molar ratios of therapeutics in the form of a prodrug. Upon delivery to a target cell, the pH-sensitive bonds are cleaved and the cocktail of active drugs is released in the cells of interest.
Wnt and Frizzled Receptors as Targets of Immunotherapy in Human Cancers
Organization: University of California, San Diego (UC San Diego)
UC San Diego researchers have identified proprietary methods for using antibodies to treat head and neck, as well as breast cancer, by specifically targeting components of the Wnt signaling pathway. Issued claims cover use of antibodies for immunotherapy [4] and for evaluating expression of components of the Wnt/Frizzled signaling pathway in human cancers. Such assessment may prove vital for evaluating the utility of drugs for specific patient populations and the efficacy of a treatment.
New Chemical Entities for Treatment of Brain Cancer
Organization: University of California, San Diego (UC San Diego)
New chemical entities have been identified and methods of use are validated for a number of candidate, small molecule therapeutics that are highly specific for cancer stem cells in the central nervous system (CNS). The compositions directly inhibit a transcriptional repressor (OLIG2), that is highly expressed in all diffuse gliomas and is found in virtually 100% of glioblastoma multiforme (GBM) cells that are positive for the tumorigenic CD133 stem cell marker. Equally importantly, except for the neural stem cell germinal zones, and ...
Space-Time Microwave Imaging for Breast Cancer Detection
Organization: Wisconsin Alumni Research Foundation (WARF)
Of the various imaging techniques used to screen women for early-stage breast cancer, X-ray mammography has proven the most effective. Despite its success, however, this technique suffers from relatively high rates of false-negative scores, requires painful compression of the breast, and exposes patients to low doses of ionizing radiation. UW-Madison researchers have now developed a novel imaging technique for detecting early-stage breast cancer called microwave imaging via space-time, or MIST for short. MIST makes use of the sharp ...
Time-Domain Inverse Scattering Techniques for Use in Microwave Imaging
Organization: Wisconsin Alumni Research Foundation (WARF)
Microwave-based imaging methods, which exploit the contrast in dielectric properties between normal and malignant tissue, offer a promising alternative to ultrasound and X-ray techniques for imaging breast tissue. Malignant tissue is most accurately detected and localized when the processing algorithms include the average properties of the actual, heterogeneous breast tissue, which vary from patient to patient; however, current techniques for solving the equations to estimate these properties suffer from nonlinearity and ill-posedness of the ...
Microwave-Based Breast Cancer Detection Using Hypothesis Testing
Organization: Wisconsin Alumni Research Foundation (WARF)
X-ray mammography is currently the most effective method for detecting early-stage breast cancer; however, mammography suffers from relatively high false positive and false negative rates, requires painful breast compression and exposes the patient to low levels of ionizing radiation. UW-Madison researchers have developed a method of identifying malignant breast tissue that uses hypothesis testing and microwave backscatter measurements. Breast tissue is illuminated with an ultrawideband (UWB) microwave pulse. The resulting backscatter ...
Estrogen-Related Receptor Gamma, a Breast Cancer Biomarker and Target for Treatment
Organization: Wisconsin Alumni Research Foundation (WARF)
Estrogen receptor-alpha (ER-alpha) has become the single most important biomarker and target for breast cancer therapy. The human estrogen-related receptor gamma (ERR-gamma) is an orphan receptor that shares significant amino acid sequence identity with ER-alpha. UW-Madison researchers have developed methods for using ERR-gamma as both a breast cancer biomarker and a target for treatment. As a biomarker, it provides a method of determining a patient’s breast cancer prognosis. Expression levels of ERR-gamma are analyzed along with the ...
Use of Estrogen-Related Receptor Alpha Status to Determine Breast Cancer Prognosis and Treatment
Organization: Wisconsin Alumni Research Foundation (WARF)
The human estrogen-related receptor alpha (ERR-alpha) is an orphan member of the steroid/thyroid hormone superfamily with no known ligand. UW-Madison researchers have developed methods for using ERR-alpha as both a breast cancer biomarker and a target for treatment. As a biomarker, ERR-alpha provides a means to determine the breast cancer prognosis of a patient. Along with the status of other genes related to breast cancer, the expression level of ERR-alpha can be analyzed to help cancer patients make informed treatment choices. A high level ...
Method of Analyzing Breast Cancer Susceptibility
Organization: Wisconsin Alumni Research Foundation (WARF)
Breast cancer poses a serious health problem to many women, but it is difficult to tell who is at risk. Because of their genetic background, 50 percent of women are at much higher risk for breast cancer, while the other half has almost no risk. If the genes linking susceptibility to breast cancer could be identified, individuals who are at risk could be notified. UW-Madison researchers have developed a method of analyzing breast cancer susceptibility based on a subject’s DNA. They used quantitative trait locus (QTL) mapping, a ...
Low Skin Dose Patient Positioning Device for Radiation Treatment of Prone Breast
Organization: Wisconsin Alumni Research Foundation (WARF)
In radiation therapy for breast cancer, the patient lies face down on a table with one breast compressed and the other pendant through a hole in the table where it is exposed to radiation. The skin is not burned because the maximum dose is not achieved until the radiation has traveled through a certain amount of tissue, called the build-up region. However, if the radiation is directed at an angle through the padded table, the padding acts as the build-up region, causing the skin to receive a greater dose. UW-Madison researchers have ...
Using Stromal Collagen to Help Diagnose and Characterize Breast Cancer
Organization: Wisconsin Alumni Research Foundation (WARF)
Biomedical imaging allows physicians to detect the onset of disease, injury and other disorders at an early stage, and to monitor their progression. UW-Madison researchers have developed an imaging method that may assist in diagnosing cancerous and precancerous conditions in breast tissue. Because breast cancer is frequently associated with the increased deposition of proteins, particularly collagen, in the extracellular matrix, the inventors developed three tumor-associated collagen signatures, or TACS, which provide novel markers for ...
Novel Splice Variants of PIPKIgamma Provide Biomarkers for Breast Cancer Diagnosis and Prognosis
Organization: Wisconsin Alumni Research Foundation (WARF)
According to the Centers for Disease Control and Prevention, more than 185,000 women in the U.S. were diagnosed with breast cancer and more than 40,000 died as a result of the disease in 2005. It is difficult to predict how the disease will progress in a given patient. Identifying individuals with poor prognosis may enable more informed treatment decisions, but few markers of breast cancer progression are available. Type I phosphatidylinositol phosphate kinases (PIPKIs) may provide additional cancer biomarkers. In mammals, ...
Stem Cell Marker for Breast Cancer
Organization: Wisconsin Alumni Research Foundation (WARF)
In patients who develop breast cancer, malignant tumors frequently begin in somatic mammary stem cells. In addition, breast tumors have a stem cell component that propagates the tumor, which may explain why some tumors recur after initially effective treatment. In order for these tumors to be successfully contained or eradicated, the cancer stem cell population needs to be targeted, a process made difficult by the lack of cell surface markers for mammary tumor stem cells. UW-Madison researchers have discovered that the low density ...
Pharmaceutical Compositions for Cancer Therapy
Organization: University of Florida
Novel Therapies for the Prevention and Treatment of Cancer
Organization: University of Florida
Cancer Therapeutic with Increased Efficacy and Reduced Side Effects
Organization: University of Florida
Spherical Surgical Cavity Sizing Tool
Organization: University of Iowa Res Foundation
Evaluation of Adenocarcinoma of the Prostate and Breast Using Anti-Dystroglycan Antibodies
Organization: University of Iowa Res Foundation
Combination Therapy for Cancer – Oral Fenretinide and Microtubule inhibitors
Organization: Children's Hospital Los Angeles
A Specific Antibody for RhoC That Can be Used for Molecular Diagnostics of Human Specimens
Organization: University of Michigan
Background Despite increased awareness of breast cancer and its prevalence, predicting patient outcome is remains difficult. Although the likelihood of metastasis is thought to be linked to the aggressiveness, growth, and size of the primary neoplasm, this is not always the case. There are many small breast cancers with a highly aggressive behavior and discouraging outcome that remain undertreated because there is no marker capable of identifying them. RhoC-GTPase is a member of the Ras-superfamily of small guanosine triphosphatases ...
Diagnosis and Inhibition of Metastatic Prostate Cancer Using Raf-kinase Protein (RKIP) Gene Products
Organization: University of Michigan
Background Cancer can be perceived as a disease resulting from breakdown of communication between and within cells. While there are many different effects, the changes in mitogen-activated protein kinase pathways play a profound role. Cancerous mutations in these pathways frequently affect Ras and Raf in the extracellular signal-regulated kinase pathway. Recent discoveries of activating mutations in human tumors have highlighted the importance of the Raf pathway in the proliferation and survival of tumor cells. In addition to a role in ...
Monoclonal Antibodies for the diagnosis and treatment of basal breast carcinoma
Organization: University of Pittsburgh
Detection of Breast Cancer using MRSI
Organization: University of Pittsburgh
Low Passage Mesenchymal Stem Cell Cell Bank from Cadaveric Vertebral Bodies
Organization: University of Pittsburgh
